ReviewCurrent hepatology reports2014
Immunosuppression in Patients with Chronic Hepatitis B.
Review in Current hepatology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Hepatitis B vaccination at birth: science, myths, and the safety net imperative.Frontiers in immunology · 2026Article
- The BTLA/HVEM axis as a key regulator for stratified functional cure in chronic hepatitis B.Frontiers in immunology · 2026Review
- Advancing HBV Diagnostics: The Role of Ultrasensitive HBsAg Testing.Diagnostics (Basel, Switzerland) · 2025Review
- Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus.The Journal of general virology · 2024Review
- Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant.ACG case reports journal · 2024Article
- JNK/c-Jun pathway activation is essential for HBx-induced IL-35 elevation to promote persistent HBV infection.Journal of clinical laboratory analysis · 2023Article
- Review
- IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases.Frontiers in cell and developmental biology · 2021Review
- Hepatitis B Virus (HBV) Genotype Mixtures, Viral Load, and Liver Damage in HBV Patients Co-infected With Human Immunodeficiency Virus.Frontiers in microbiology · 2021Article
- Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis.International journal of rheumatic diseases · 2020Review
- A global scientific strategy to cure hepatitis B.The lancet. Gastroenterology & hepatology · 2019Article
- Disparities in Hepatitis B Virus Infection and Immunity Among New York City Asian American Patients, 1997 to 2017.American journal of public health · 2018Article
- Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians.Clinical medicine (London, England) · 2018Review
- RFX1 participates in doxorubicin-induced hepatitis B virus reactivation.Cancer medicine · 2018Article
- Interleukin-35 Level Is Elevated in Patients with Chronic Hepatitis B Virus Infection.International journal of medical sciences · 2018Article
- Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.Journal of global oncology · 2016Article
- Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations.World journal of hepatology · 2016Review
- Future Therapy for Hepatitis B Virus: Role of Immunomodulators.Current hepatology reports · 2016Review
- Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection: the differential serological diagnosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Review
- Screening for hepatitis B in patients with lymphoma.Proceedings (Baylor University. Medical Center) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After hepatitis B virus (HBV) infection, HBV DNA persists in minute amounts in hepatocyte nuclei even in individuals with "resolved" infection. Viral replication and development of liver disease depend on the balance between viral mechanisms promoting persistence and host immune control. Patients with active or inactive disease or resolved HBV infection are at risk for reactivation with immunosuppressive therapy use. HBV reactivation varies from a clinically asymptomatic condition to one associated with acute liver failure and death. We review recent studies on HBV reactivation during immunomodulatory therapies for oncologic, gastroenterological, rheumatic, and dermatologic disorders. Risk calculation should be determined through HBV screening and assessment of immunosuppressive therapy potency. We also discuss monitoring for reactivation, prophylactic antiviral therapy, and treatment of reactivation. Prophylactic antiviral treatment is needed for all HBsAg carriers and selected patients who have anti-HBc without HBsAg and is critical for preventing viral reactivation and improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.